Status:
COMPLETED
A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-85 years
Brief Summary
Evaluate the efficacy and safety of Disitamb Vedotin in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer
Detailed Description
The main goal of this clinical trial is to examinie the utilization of RC48 in different HER2 statuses, elucidating its clinical outcomes and safety, and investigating the factors that influence its c...
Eligibility Criteria
Inclusion
- histopathologically or imaging-confirmedlocally advanced or metastatic breast cancer ;
- HER2-positive or low status;
- the function of major organswas normal, no treatmentcontraindications , andthe estimated survival time was more than 2 months;
- at least one extracranialmeasurable lesion or osteolytic or mixed bone metastases inaccordance with the Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1);
- the clinical data were complete and traceable.
Exclusion
- age \<18 ye ars old;
- other concurrent cancers;
- patients who rece ived RC48 as a neoadjuvant or adjuvant regimen；
- Incomplete medical data.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06168227
Start Date
October 1 2021
End Date
September 30 2023
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China, 210000